Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Zymeworks Inc ZYME

Healthcare Biotechnology
Zymeworks Inc. is a global biotechnology company. The Company is engaged in the discovery, development, and commercialization of multifunctional biotherapeutics to treat cancer and other serious diseases. Its complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop differentiated antibody-based... see more

Recent & Breaking News (NDAQ:ZYME)

Jazz Pharmaceuticals and Zymeworks Announce Exclusive License Agreement to Develop and Commercialize Zanidatamab, a HER2-Targeted Bispecific Antibody

PR Newswire October 19, 2022

Zymeworks to Host Third Quarter Results Conference Call

Business Wire October 18, 2022

Zymeworks Completes Plan to Become Delaware Corporation

Business Wire October 13, 2022

Zymeworks Announces Results of Special Meeting

Business Wire October 7, 2022

Zymeworks Reminds Shareholders to Vote FOR its Redomicile

Business Wire October 4, 2022

Zymeworks Announces Participation in Upcoming Investor Conferences and Early Research & Development Day

Business Wire October 3, 2022

Independent Proxy Advisory Firm ISS Recommends a Vote FOR the Zymeworks Redomicile

Business Wire September 26, 2022

Independent Proxy Advisory Firm Glass Lewis Recommends Zymeworks Shareholders Vote FOR Redomicile

Business Wire September 16, 2022

Zymeworks Reports Preliminary Phase 1 Trial Results for Zanidatamab Zovodotin (ZW49) at European Society for Medical Oncology Annual Congress

Business Wire September 12, 2022

Zymeworks Announces Filing and Mailing of Materials for the Special Meeting to Approve Redomicile to Delaware

Business Wire September 8, 2022

Zymeworks Announces Release of ESMO Abstract for Phase 1 Study of Zanidatamab Zovodotin (ZW49) in Solid Cancers

Business Wire September 4, 2022

Zymeworks Provides Corporate Update and Reports Second Quarter 2022 Financial Results

Business Wire August 4, 2022

Zymeworks Announces Participation in Upcoming Investor Conferences

Business Wire August 1, 2022

Zymeworks Announces Oral Presentation of Data from Phase 1 Study of Zanidatamab Zovodotin (ZW49) in Solid Cancers at European Society for Medical Oncology (ESMO) Congress 2022 in Paris

Business Wire July 25, 2022

Zymeworks Reports Inducement Grant to New Chief Scientific Officer

Business Wire July 22, 2022

Zymeworks to Host Second Quarter Results Conference Call

Business Wire July 21, 2022

Zymeworks Announces Plan to Become a Delaware Corporation

Business Wire July 15, 2022

Zymeworks Appoints Dr. Paul Moore as Chief Scientific Officer

Business Wire June 27, 2022

Zymeworks Adopts Limited-Duration Shareholder Rights Plan, Enabling All Shareholders to Realize Full Value of Company

Business Wire June 10, 2022

Zymeworks Announces Participation in Upcoming Investor Conference

Business Wire May 27, 2022